Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that the European Commission has approved TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin as a first-line treatment for adults with metastatic or recurrent nasopharyngeal carcinoma not amenable to curative surgery or radiotherapy.
The approval is based on data from the Phase 3 RATIONALE-309 trial, which demonstrated a statistically significant improvement in progression-free survival. Patients receiving TEVIMBRA plus chemotherapy saw a 48% reduction in the risk of disease progression or death, with median progression-free survival of 9.2 months versus 7.4 months in the placebo arm.
An updated analysis showed consistent efficacy and a sustained overall survival benefit, with median overall survival reaching 45.3 months for the TEVIMBRA group compared to 31.8 months for placebo.
TEVIMBRA plus chemotherapy was generally well tolerated, and no new safety signals emerged. The most common Grade 3 or 4 adverse reactions were neutropenia, anaemia, and thrombocytopenia.
This marks the second European Union approval for TEVIMBRA in 2025, expanding its existing indications across gastric, oesophageal, small cell lung, and non-small cell lung cancers.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
INOVIO prices USD25m public offering
Biocon Biologics' Denosumab biosimilars receive European Commission approval